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In the process of fibrinolycis (that is. fibrin rewlution medi- 
ated by plasmin). the major physiologic actirator of the 
proenzyme plasminogen is believed to b; the tissue-type 
piasminogen activator (i-PA1 (1) produced and released into 
lhc blood from thr endethelium IZI IF& I). However. two 
distinct fibrinalytic proaclivator syste& have been charac- 
terized in the blood 13.4). In the factor XII-dependent 
pathway. the conversion of plarminogen IO plasmin involves 
activation of factor XII. prekallikrein and an additional 
proactivator 12-S). In the umkinare-typ system. a single 
chain proenzyme (prourokinasel is converted by activatmn 
into a plarminogen activator 16). In vilro. ihe lactor XII- 
dependent aad urokinase-type pathways can both be acti- 
vated by t-PA (7.8) a proccr> probably mcdiater. by the 
generation of plarmin (7). 
To date. the two tibrinolytic proactivator cysteins have 
been characterized by test tube experiinents. and lhe rele- 
vance of the obtained results for in viva tibrinolysis has not 
been determined. Treatment of patients with recombinant 
I-PA (n-PA) (or streptokinase) now provides a relevant 
model for the study of in viva interrelationr between plas- 
minugen activator bystems. The purpose cf the study was to 
asst~ the role of the fibrinalytic proactivator syrrem after 
treatment with n-PA or streptokinase in patients with acute 
myacardlal mfarction. 
Methods 
Study patients mtd tmtrncn, groups. The groups of pa- 
tients Waled with n-PA or placebo have been previously 
dexnbed 191. In brief. betweenOctober I. 1987 and June I. 
1988. all paGents admitted to the coronary care unit. Ribs 
County Huspital in Esbjerg. with suspected myocardial 
infarction were clinically evaluated for inclusion. Inclusion 
criterta were symptoms indicative of myocardial infarction 
of a duration of c.5 h. age bewcen 18 and 75 years and 
palentr not fulfilling a set of previously described exclusion 
crwria (91. Patients were consecutively and mndumly allo- 
cated to a double-blind treatment administered inlrave- 
nou5ly: a bolus injection of heparin WQll IU) followed by a 
3 h infwon of either placebo or rt-PA (IO0 mg) Kienentech 
Inc. supplied by Boehringer lngelheim International GmbH) 
admini&d ai a bolos injection of IO mg followed by M. 20 
axI 20 mg in each of the subsequent hours. Thereafter. all 
patients received heparin (INNI NJ/h) for the next 21 h. 
A total of 56 patients were included in this trial. The 
diagnosis was myocardial infarction in 23 of the 34 patients 
allocated to n-PA treatment and in 17 of the 22 patients 
allocated to placebo treatment. Two patients with myocar- 
dial infarction treaed with n-PA died 2 and 3 h. respec- 
lively. after initiation of treatment. One patient with myo- 
cardial infarction allasated to placebo treatment was 
withdrawn from treatment and hlwd sampling because of 
the need of a pacemaker. 
For this derailed biochemical invrsrigarion. we studied 
the initial seven patients with uncomplicated myocardial 
infarction allocated to treatment with +Pk (median age 62 
years, range 54 to 74) and the initial seven patients with 
uncomplicated myacardial infarction allocated to placebo 
treatment (median age 56 years. range 48 to 571. To subrtan- 
tiate our findings in these patients (see Results). we ituluded 
a Sroup of seven patients with myocardial infarction (median 
age 63 years. range 30 to 751 treated with a I h infusion of 
streptokinare (1.5 million II) (Behringwerke. AG) studied in 
February 1989. Additional exclusion criteria for streptoki- 
nase trentmcnt were documented infection with beta- 
hemolytic streptococcus within 6 months. previous strep- 
tokinasc treatment or documented allergy to streptokinase. 
The local Ethics Committee approved the invcrrigation 
and the declaration of Helsinki was observed. All patients 
gave informed consent before inclusion in the study. 
Blood sampling and handling. Blwd was collected 
through a veoous cannula inserted in the forearm not used 
for administration of the drug or placebo treatment. The 1st 
10 ml of blood was discarded. and samples were collected 
with minimal stasis by meatu of a standardized technique 
(IO) into 5 ml siliconized evacuated glass tubes with sodium 
citrate (0.5 ml of 0.129 mollliter sodium citrate. Vacutainer A 
P@re 1. The plasminogen activating .WII~ of
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3206 SBW-E. Becton Dickinson) and placed in an ice bath. 
Within 5 mitt of collection. blood sanmles were centrifuged 
at 2,M)(I g for 20 min at 4°C and plasma specimens of Gill 
in plastic tubes were frozen and kept at -WC until assay in 
one session to eliminate interassay variation. 
.%mplia~ periods. Blood samples were collected from 
patients allocated to treittment with R-PA or placebo immc- 
diately before tperiod 0) and 2% h @riod I). 4 h @wiod 21. 
!? h (period 3) and 24 h (@xl 4) after initiation of 
treatment. as well as in the morning of Ihe third (period 5) 
and fourth (period 61 day after dmissioo. Taken iu a 
representative of the patient’s habitual stattu. additional 
samples were collected in the morning S weeks after dis- 
cha& from hospital (period 7). In the streptokinase .gmop, 
collection of blood samdes was Smiled to periods 0. I ami 6. 
Dropouts in the blood &+mpling procedure did tmt occur. 
Assws. Activirv of r-PA was assessed in the reaular 
euglobuk fraction inihe presence of a previously optiiiized 
so!utian of Cl-esterase inhibitor (Behrinewerke AGI to 
- quench all other activator activities (II). 
Plosminogen activator activity of the focrur XII- 
dependent sysrcm was assayed as described previously 
(I l-13) in the dextran sulfate euglohulin fraction of plasma in 
the presence of sodium flufenamate and added specific 
antibody neutralizing activities of both t-PA and umkinase 
(Organon Tekoika) (13). 
Urokinose-type plnsminogen activator activity WBE caku- 
Isted as the difference between the total activity of the 
dextmo sulfate euglobulin fraction (with addition ofantibod- 
ies to t-PA) and the factor XII-dependent portion. 
Plosminogen activator ucfivify was determined on fibrin 
elates oreoared from olasminwert-rich librinoeen as de- 
kxd’in ietailelsewh;re(lI-Ii). The lower de&ion limb 
of the fibrinogen batch was I6 mm’. Each sample was 
assayed in trip&ate using the product of two perpendicular 
diameters of the circular zones of lysis as measurements. 
The plasminogen activator activity of t-PA was expressed in 
nplre 2. Median activities of tissue-type tas- 
minOSen activator (I-PA act.1 (top pwl. adi. 
Nate) and relative concenlradanr lmedanl of 
plarmimw in plasma tbmem paeet. wdtnnte~ 
ic seven padcots wirh acut* myoardial inlaw 
lion treated wtb recombinant I-PA I~.PAI and 
hewin (blood samples with 1.1 and wkhwl 
I@1 PPACKl. Ranee of t.PA acwities t21/. h) 
and 25 10 75 ime&rcentile range of rrlatire 
coocenttianr of ptasmioogen tvenkat bars) 
we shown. solid her et base&e indicates wea!- 
meat period and opa bar indicates hepann. 
Sampling periods: pre~reaorwnr (p et and 2.25. 
4. 12 and 24 h after inidadoo of ~rearment. on 
the morning of the 3rd and 4th days after 
admission and 8 weeks after dischcharg Sfe text 
for definition of PPACK. 
mm’ and that of the factor XII-dependent and arokinase- 
type systems in arbitrary blood activating unit, IBAU) per 
mlafplasma(perdefinitioo there are 100 BAIJ in the dextran 
sulfate euglobulin fraction prepared from I ml of pooled 
normal plasma Il3Jl. 
bc f/w slr~pfproti,lurr-rr~orrd porirnrr. rpecitic recording 
of factor XII-dependent and urokinase type fibrinolytic ac- 
tivity in period I war no, powble because of the law 
contribution of activity not &enchable by ,peciiic anrihod- 
its to t-P*. 
Other awns. We determined the corxeotrationr of olas- 
mmogen and. alphal-antiplarmin in pIalma by funcr;onal 
methods tl4.151. Concentrations of antieen factor XII were 
determined by the Laurell technique ising monorpecific 
antiserum (Nordic). The actiw!y of factor XII and prekal- 
likrem ua, delermined as described previously (16.17). 
Reults are expressed relative to normal pooled plasma. 
Preventkm of artifaaual in vitro activation of Mwittdysis 
variables (Fig. 2). High concentrations of t-PA in blood 
rampIe\ obrained from patients who undergo chromtiyris 
can aclivatc the tibrinolytic system in vitro and thus the 
determination of tibrinolysis variables may not be repre- 
sentative of their concentrations in viva. Therefore. b\ 
gentle inversion of the glass tube immediately (within sec- 
ond%) after collection. some blood samples were mixed with 
10 &I of a 5 mmollliter wlution of D-Phe-Pro-Arg-CH,CI 
IPPACKI (yielding a concentration of IG ml PPACK per 
ml of bloat). which is B synthetic inhibitor of t-PA, thrombin 
and plasmin (18.19). Tbe solution of PPACK (5 mglvial. 
Calbiocheml was prepared by reconstituting one vial in 
1.9 ml of 0.1 moliliter of hvdrochloric acid and storinr 50 ul 
specimens at c-2O’C until thawin8 immediately before use. 
Supplementation of blood samples with FlACK did not 
completely eliminate I-PA activity in sanples collected 
during and I h afier n-PA treabnent (Fig. :. top panel). 
However. the residual low levels af t-PA in Sam&s contain- 
ing PPACK do not seem to cause significant invitm acliva- 
lion of the fibrinolytic bystem. 
Same blood samples collected from apparently healthy 
volunteers were supplemented immediately after collection 
with R-PA to yield the highest recorded t-PA activity 
(184 mm’. which corrcswnds to 90 ng of r&PA per ml of 
blood) (Fig. 2. top p&l) and plasma specimens were 
prepared and stored as described. After thawing and assay. 
measurements of the n-PA-enriched plasma did wt differ 
from those of the control sample: plasminogen activity (82% 
and 6411 or alphaz-antiplasmin activity (113% and 117%). 
Furthermore. when we compared plasminogen canccntra- 
tious tn hampIes with or without PPACK rupplemenlation. a 
small but statistically significant difference (p ,‘: 0.05) was 
observed only during the rt-PA treatment (Fig. 2. bottom 
panell. Therefore. a standardized and rapid processing of 
blood samples obtained from patients undergoing throm- 
bolytic therapy. as meticulously adhered to in our study. is 
nearly as impOrtant as employing synthetic inhibitors of 
fibrinolysis or antibodies to l-PA for preventing in vitro 
artifacts (18.19). 
Control experiments revealed that neither PPACK nor 
the concentration of plasminogen in the samples aBected 
determination of lactor XII-dependent and urokinnse-type 
fibrinolytic activity. In these assays. we could quench t-PA 
activity in all samples supplemented with PPACK to a 
net&ible extent (<2 BAUlmll by the use of specific anti- 
bodies lo t-PA. In accordance with previous observations 
(181. PPACK did not alfcct assavs other than those for the 
detemdnation of t-PA activity.‘Thus. we determined all 
presented variables in blood samples supplemented with 
PPACK. 
Hcmodilutioa. In both the ri.PA and placebo groups, the 
hematcwit decreased significantly lp < O.lNIl from period 0 
to nadir levcl~ in period 3. followcti by an incrcasc to period 
7. To correct for this hemodiluticu, all prcscntcd variables 
were multiplied by the factor: hematoerit of period Olhema- 
twxit of period x (the x designates periods 0 to 7). The 
statistical evaluation showed similar trends whether or ttot 
variables were corrected. hut only eomcted data arc prc- 
scented. 
Statlstks. Unless otherwise stated, data arc reported as 
the median values. with the range in brackets. DilTcrcnecs 
between e.ro”~s WOR evaluated bv twnvaramctric two-way 
analysis if &iance (20). Di&nees within groups w&e 
estimated bv the Friedman chi-square test. If statistical 
significance was found. the Wilcox&n paired test was used to 
compare appropriate periods. The Speamtan rank-order 
correlation cociiicient was used to test the association be- 
tween two variables. A p value <O.OS ltwo-tailed test) was 
considered statistically significant. 
Results 
Factor XIIde~~ndent lihriwlvtle activity aflcr et-PA and 
rlreptokincx (Fi. 3). We obsc&ed fro sigbificant deviation 
in factor XIl.deoendent fibrinolvtic activilv in the seven 
placebotreated patients @hi-s&e = 10.27: p > 0.10). hut 
in the seven rt-PA-trea!ed patients. the activity decreased 
significantly from pretreat& values (chi squ& = 29.38. 
p < O.tMI). This activity remained deprcrsed during the 1st 
h days after initiation of treatment (aI deviations between 
periods 2 to 6 yielding p > 0.05). From period 6 to period 7. 
factor XII-dependent aclivity increased in the n-PA group 
(p < 0.05). The activity in the placebo group was signifi- 
cantly higher than in the n-PA group (periods I to 6. p 4 
xnr-- 
&we 4. Median concenm~onr @rdtnW m plasma 
wd IS to 75 iaerpereentite range of factor XL, t., md 
pr+ikre/n (01 in seven patents wrh acute myocar. 
$al mfarctlon treated with n-PA. Formal a5 in Figure 
m- 
0.05). These findings indicate that treatment wth rl-PA 
~BUECS a prolonged depletion of the factor Xlldependenr 
tibriwlytic system in patients with myocardial infarction. In 
the group of patients treated witb streptokinare. factor 
Xlldependent activity also decreased significantly (p < 
0.05. Wilcoxon test). No significant difference in activity 
among the three groups was found in penod 0 tp > 0.O.V. 
Umkinase-type fibrinolytic activity did not show significant 
deviations between wmpting periods m the placebo group 
(chi square = 9.83. p > 0.10). the R-PA group lchi square = 
8.43, p > 0. IO) or the streptokinase group (p > 0.10). 
Antigen feetor XII and prekattikrein activity (Fig. 41. We 
next studied individual components of the factor XII. 
dependent fibrioolytic system (Fig. Il. In the seven n-PA- 
treated patients. the deviation between sampling periods of 
concentrationsofantigen factor Xit tchi square = 21.74. p < 
0.01) and activity of prekallikrein (chi rquare = 21.83. p i 
O.Oll in plasma did not parallel the much earlier decrease in 
factor XII-dependent fibrinalytic actwdy (Fig. 31. We ob- 
served a small but statistically significant decrease tp < O.OSI 
from the pretreatment value for factor XII only 24 h after 
initiation of treatment Iperiods 4. 5 and 6) and for prekal- 
likrein on the 4th day after admission Iperiod 6. p < 0.051. 
These fluctuationr of factor XII and prekallikrein may be 
associated with an acute phaw response or other metabolic 
changes in patients with early myocardial infarction. 
Role uf activation prwess in plasma samples. Finally. we 
studied whether the low factor Xltdependent tibrmalytic 
activity in patients treated with n-PA was related to Q 
functionally defective activation procers in the plasma ram- 
ples (3.5). In randomly selected n-PA-treated patients. 
concentrations of factor XII in plasm;, determined by the 
antigen and functional ssay correlated significantly tn = I?. 
r = 0.68, p 4 0.03). To ensure that the determination of 
factor XII-dependent fibrinolytic activity was not influenced 
by the low concentrations of plasminogen (Fig. 2. nghl 
panell. we supplemented patient samples with purified plas- 
minogen 10 yield concentrations > IS@?& relative to normal 
pooled plasma. As previously (III. we observed identical 
activity in the samples supplemented with plasminogen and 
the samples with .M addition of plasmin&en. When we 
mixed (I + II the dextran sulfate euglobulin fraction from 
the patlents with that from normal pwled plasma, factor 
XII-dependent tibrinolytic activity of thy mix did not deviate 
from rhe average of the individual euglobulin activities 
124.1 BALI/ml [range 15.7 to 411 and 24.0 BAUiml [range I8 
to 34.61. respectivelyl ‘p > 0.20). These observations indi- 
cate that factor XII and orekallikrein are functionallv active 
and that the activation &ess of the factor XII-dependent 
fibrinolytic pathway is not defective in the patient samples 
(51. 
In this study, we determined the endogenous factor 
XII-dependenl and urokinasetype librinolyiic activity in a 
group of patients with acute myocwdial infarction treated 
with n-PA t IW mg. 3 hinfusionlorstreptokinase (I.5 million 
U. I h infusion) and compared the results with those 
obtained m a placebo-treated group of patients. 
Factor XIIdepeudml tihrinolytk activity. We observed 
only insignificant deviations in factor Xlldependent Ibrin- 
olytic activrty in the placebo group. whereas activity de- 
creased significantly in the patients treated with n-PA (Fig. 
3). Our results indicate that the decrease is related to an 
exhaustion in viva of the main proactivator of this fibrin- 
olyuc pathway(Fig. It. Ftrst. we can exclude theoccurrence 
of in vitro artifacts related to activ~!ion of the tibrioolytic 
system and that the concentration of plssminogen in the test 
samples influenced the specific determination of factor XII- 
dependent fibrinolytic activity. Second, enzymatically active 
factor XII and prekallikrein are prerent in sufficient amounts 
in plasma (Fig. 4) to ensure complete activation of the 
proactivator (51. ‘Ihird. our mixing experiments indicate that 
thr activation procc\~ is no, defective in the paden, samples 
13.5). For example. if an increase of an inhibitor caused ,he 
observed depression of Actor Xll.dcpcndent fibrinolytic 
activity IFig. 31. it alro would have inhibited the generation 
of activity in normal p&cd plasmn. This would result in 
lower factor XILdepe,,dent tibrinolytic aclivity in the mixed 
eunlobulio fractions when compared with the estimated 
a&age of the individual activiti&. 
These indicatmns of a decrease in viva of the factor 
XII-dependent fibrinolytic proactivator arc of panicular in- 
terest because our investigation is the firsl to elucidate ils 
behavior in a pathophysiologic condition. The ~iparertt 
exhaustion of the praactiva.or does not seem to be an 
r,-PA-specific process, hecawe factor XII-depndea, fibrin- 
oly,ic activity also decreased in the weptokina-treated 
patients IFig..31. The common underlying mechanism might 
be related to an activation ~roccss in viva of this tibrinolvtic 
pathway by generated pl&in (7.8) (Fig. I aad 21 and D siow 
rcsynthrsis of ihe proactivator. 
Urddnssc-type Sbriiyttt activity. In contrast to these 
observations. we observed no significant deviations in uroki- 
nasc-type fibrinolytic activity. However. the turnover 01 
prourokinase is rather rapid (its plasma half-life is approxi- 
mately 5 min) (21). bo we cannot exclude that a transienl 
deoktion of this oathwav has taken olace. 
‘Clinical impl&anr.‘Our rcsultf may have important 
clinical imolications. If the factor XII-deoendent tibrinolvtic 
pathway decomcs activated in viva b; administration of 
thrombolytic agems in patients with myocardial infarction. it 
may contribute to coronary thrumbolysis. Conversely. the 
remarkably prolonged depression of factor XII-dependent 
tibrinolytic activity could be deleterious if it is related to the 
dcvclo~mcnt of early recurrent coronary thrombosis. which 
is a major problem associated with th:cmboly,ic therapy 
(22). These arpect, ofour study need to be explored further. 
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